
Scan how other high-performance computing and crypto infrastructure stocks compare on contracts, power access, and balance sheets by running the curated 53 AI infrastructure stocks alongside Core Scientific's latest update.
To own Core Scientific, you need to believe the high performance computing and crypto infrastructure platform can turn its large contracted pipeline into durable cash flow before balance sheet pressure bites. According to DanielOliveira, an investor in the Simply Wall St Community, the real story is not the Q3 revenue beat but whether those big AMD related Texas contracts actually get the power they need.
The recent quarter confirmed that existing capacity can generate strong adjusted EBITDA, while the huge net income line came from a non cash warrant gain that does not fix negative equity or a cash runway of less than one year. ERCOT’s upcoming power allocation decisions for Pecos and Hunt remain the key short term catalyst and the biggest operational risk because they influence both build timing and funding options.
The most relevant recent update is Core Scientific’s Q3 deck that lays out more than 1 GW of contracted load, including 590 MW for CoreWeave and 530 MW tied to AMD and a credit backed neocloud. DanielOliveira, a Simply Wall St Community investor who wrote the Narrative, argues that about 56% of that AMD linked capacity depends on the Texas Pecos and Hunt sites flagged as conditional in ERCOT’s Batch Zero process.
Those conditional allocations matter because first delivery at Pecos is listed for the first half of 2027 and at Hunt for the first half of 2028, while the business currently has less than one year of cash runway and negative shareholders’ equity. Your assessment of Core Scientific probably comes down to how you weigh that contracted backlog against the timing uncertainty on ERCOT approvals, potential delays to energizing load, and the funding gap that could open if ramp up slips.
The narrative from DanielOliveira pins fair value at US$12.76 mainly because ERCOT outcomes for Pecos and Hunt are treated as the hinge. If both Texas allocations hold, the AMD linked contracts are viewed as underappreciated compared with how the wider market currently treats Core Scientific’s Texas exposure.
Uncover why Core Scientific's fair value indicates a 4% potential downside to its current price, which leaves little room for error.
One big swing factor you might focus on is Core Scientific’s heavy construction bill for those AMD and CoreWeave projects. The lowest analysts were penciling in revenue of about US$1.8b and earnings of roughly US$220.7m by 2029, yet still treated the stock as stretched. This shows how far opinions can differ before this Q3 update is fully absorbed.
Explore 3 other Core Scientific fair value estimates, including one that suggests it could be worth just $16.00.
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
If the Core Scientific story has sharpened your thinking about contracts, funding, and risk, you can broaden that lens across the market using a few focused stock shortlists.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com